ID-8 is an inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).[1]
Actions biochimiques/physiologiques
ID-8 sustains self-renewal and pluripotency of mouse embryonic stem cells (ESCs) in vitro. Stimulates proliferation at a steady rate (observed in serum-free media supplemented with 10 μM over a 30 day period).
Sustains self-renewal and pluripotency of mouse embryonic stem cells (ESCs) in vitro.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Faites votre choix parmi les versions les plus récentes :
The purpose of our study was to validate perfusion quantification in a low-perfused tissue by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with shared k-space sampling using a blood pool contrast agent. Perfusion measurements were performed in a total of seven
Current molecular pharmacology, 9(3), 272-279 (2015-05-27)
Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and
A High-Throughput Screen Identifies DYRK1A inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation
Monteiro M B, et al.
Journal of the American Society of Nephrology, ASN-2018040392 (2018)
Annals of translational medicine, 8(12), 752-752 (2020-07-11)
Paclitaxel is a widely used clinical first line chemotherapy drug for ovarian carcinoma. Tanshinone I (Tan-I) is one of the vital fat-soluble components, which derived from Chinese herbal medicine, Salvia miltiorrhiza Bunge. Herein, we evaluated whether Tan-I could enhance the
Molecular cancer therapeutics, 20(4), 716-725 (2021-02-05)
Ovarian cancer is a diverse class of tumors with very few effective treatment options and suboptimal response rates in early clinical studies using immunotherapies. Here we describe LY6/PLAUR domain containing 1 (LYPD1) as a novel target for therapeutic antibodies for
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
